What every developer should know to maximize BTD value
by Dr. Jason Mercer, Ph.D., RAC and Strategic Program Innovator
The Food and Drug Administration’s (FDA’s) Breakthrough Therapy Designation (BTD) program offers sponsors a powerful opportunity to expedite the development of promising therapies for serious or life-threatening conditions. For gene therapy developers navigating a novel therapeutic modality, BTD can be critical to getting to and through the FDA more efficiently. However, realizing the full benefit of BTD requires careful planning, strategic resource allocation, and early alignment with regulatory expectations.
In this post, we’re sharing insights from a gene therapy product that successfully obtained BTD — highlighting the qualification strategy, the immediate development benefits, and the challenges that limited the program’s potential to expedite approval.
Understanding Qualification Requirements for an FDA Breakthrough Designation Application
To be considered for BTD, a drug or biological product must meet two criteria. The submission must:
- Target a serious or life-threatening disease or condition
- Demonstrate preliminary clinical evidence of substantial improvement (over existing therapies on at least one clinically significant endpoint)
BTD In Action: Gene Therapy for a High-Risk Vascular Condition
In this case, the gene therapy was developed to treat a vascular condition associated with a high risk of limb amputation, easily satisfying the first criterion.
Meeting the second criterion required a careful strategy. The sponsor had to align three critical elements:
#1 Data Maturity & Availability
Clinical (not just preclinical) data are required. Although “preliminary” data are acceptable, they must be sufficiently mature.
For example, in our work with another sponsor, the BTD request was initially submitted based on interim results at the 12-week mark of an ongoing study. The FDA determined that the data were too early and recommended resubmission after study completion. The sponsor ultimately obtained BTD following resubmission with the full data set.
The lesson here? Even preliminary data must be sufficiently mature to support a BTD request.
#2 Demonstration of Substantial Improvement
The sponsor had to show a meaningful advantage over existing therapies. Here, no approved therapies existed for the condition, simplifying comparisons — the therapy demonstrated clear superiority over placebo.
#3 Clinically Significant Endpoints
The sponsor explored multiple biomarkers but ultimately relied on complete wound healing as the primary endpoint. The FDA agreed that complete wound healing was clinically meaningful for this condition.
Immediate Benefits of Breakthrough Therapy Designation
Once granted, BTD provided tangible benefits that positioned the sponsor to accelerate development, including:
- Real-Time Regulatory Feedback
- The product’s BTD status enabled more frequent communications with the FDA on development plans.
- Faster Resolution of Regulatory Questions
- With high-level FDA engagement, the sponsor could more precisely address outstanding gaps. Access to senior decision-makers at the Agency allowed the sponsor to navigate regulatory flexibility with greater agility, minimizing unnecessary delays.
- Eligibility for Rolling & Priority Review
Challenges Encountered and Lessons Learned
Despite the benefits, several challenges emerged that limited the sponsor’s ability to fully capitalize on their BTD. Before pursuing BTD, sponsors should:
#1 Allocate Resources Strategically
The frequent interactions enabled by BTD status require substantial sponsor resources. Strategic planning is essential to identify key decision points, develop meeting requests and briefing documents, and ensure readiness for discussions. Sponsors must anticipate and allocate sufficient regulatory and technical support early.
#2 Critically Assess Development Readiness
Sponsors also need to understand whether their entire development program — clinical, manufacturing, and CMC — is ready to support accelerated timelines.
In this case, the clinical data package was ready to support BLA submission. However, changes made earlier in the manufacturing process required additional validation activities, ultimately delaying submission despite regulatory readiness.
Early alignment between clinical and CMC strategies is key to fully realizing the benefits of expedited pathways.
How Strategic Planning Maximizes BTD Value
BTD can significantly accelerate drug development for therapies targeting serious or life-threatening conditions. However, success depends not only on qualifying for the program but also on proactively preparing development, manufacturing, and regulatory strategies to match an accelerated timeline.
Early planning — especially regarding clinical endpoint selection, maturity of clinical data, and manufacturing process stability — is critical to maximizing the value of BTD and bringing much-needed therapies to patients more efficiently.
If you are considering pursuing BTD for your product, early strategic consultation can help avoid common pitfalls and optimize your development path.
Streamline Product Development with Strategic Gene Therapy Regulatory Services
Strategic preparation is key to unlocking the full potential of expedited programs like BTD. Getting to and through the FDA with a novel gene therapy requires more than strong science — it requires asking the right questions at the right time, with the right regulatory strategy behind them.
With proven experience supporting successful BTD submissions across multiple sponsors, we can help you build a robust, efficient regulatory strategy tailored to your product. Reach out today to start a conversation about accelerating your development program.
| Bring Critical Gene Therapies to Patients Faster |
gET sOCIAL